Similar articles

• Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.

  O'Brien RT. O'Brien RT. Ann N Y Acad Sci. 1974;232(0):221-5. doi: 10.1111/j.1749-6632.1974.tb20588.x. Ann N Y Acad Sci. 1974. PMID: 4528431 No abstract available.
• [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].

  Cartei G, Cazzavillan M, Chisesi T, Battista R, Barbui T, Dini E. Cartei G, et al. Minerva Med. 1978 Mar 17;69(13):811-21. Minerva Med. 1978. PMID: 643223 Italian. No abstract available.
• Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.

  Nienhuis AW, Delea C, Aamodt R, Bartter F, Anderson WF. Nienhuis AW, et al. Birth Defects Orig Artic Ser. 1976;12(8):177-85. Birth Defects Orig Artic Ser. 1976. PMID: 795481 Review. No abstract available.
• Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.

  Dutta AK, Ray R, Chandra S, Bhattacharya DK. Dutta AK, et al. J Assoc Physicians India. 1988 Jul;36(7):463-4. J Assoc Physicians India. 1988. PMID: 3204100 No abstract available.
• Clinical management of beta-thalassemia.

  Graziano J, Piomelli S. Graziano J, et al. Tex Rep Biol Med. 1980-1981;40:355-64. Tex Rep Biol Med. 1980. PMID: 7034276 Review. No abstract available.